Technical Analysis for MYL - Mylan Inc.

Grade Last Price % Change Price Change
grade C 21.66 -1.41% -0.31
MYL closed down 1.41 percent on Friday, January 17, 2020, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical MYL trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Jack-in-the-Box Bullish Bullish Swing Setup -1.41%
Upper Bollinger Band Walk Strength -1.41%
Inside Day Range Contraction -1.41%
Overbought Stochastic Strength -1.41%
Upper Bollinger Band Touch Strength -1.41%
Expansion Breakout Bullish Swing Setup -1.77%
Pocket Pivot Bullish Swing Setup -1.77%
Wide Range Bar Range Expansion -1.77%
Stochastic Reached Overbought Strength -1.77%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, and injectable or transdermal patch forms, as well as API. It also focuses on developing APIs with non-infringing processes to partner with manufacturers. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable, nebulized, and transdermal products for life-threatening conditions. Its products include EpiPen Auto-Injector to treat severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. The company also manufactures and sells injectable products in various therapeutic areas for the hospital setting; supplies APIs for the manufacture of antiretroviral (ARV) drugs to treat HIV/AIDS; offers finished dosage form (FDF) products in the ARV market; and manufactures non-ARV FDF products, as well as focuses on developing, manufacturing, and commercializing dry powder inhaler delivery platform. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.
Health Life Sciences Pharmaceutical Industry Pharmaceuticals Pharmaceutical Industry In China Pharmaceuticals Policy Active Pharmaceutical Ingredients HIV/Aids Healthcare Institutions Disorder Generic Drug Generic Pharmaceutical Products Pharmaceutical Wholesalers Drug Manufacturers Injectable Products

Is MYL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 32.23
52 Week Low 16.63
Average Volume 6,245,557
200-Day Moving Average 20.05
50-Day Moving Average 19.13
20-Day Moving Average 20.57
10-Day Moving Average 21.27
Average True Range 0.63
ADX 37.2
+DI 32.02
-DI 11.29
Chandelier Exit (Long, 3 ATRs ) 20.50
Chandelier Exit (Short, 3 ATRs ) 20.48
Upper Bollinger Band 22.19
Lower Bollinger Band 18.94
Percent B (%b) 0.84
BandWidth 15.78
MACD Line 0.70
MACD Signal Line 0.61
MACD Histogram 0.0896
Fundamentals Value
Market Cap 11.62 Billion
Num Shares 536 Million
EPS 1.24
Price-to-Earnings (P/E) Ratio 17.47
Price-to-Sales 1.72
Price-to-Book 1.61
PEG Ratio 1.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.58
Resistance 3 (R3) 22.65 22.41 22.43
Resistance 2 (R2) 22.41 22.18 22.38 22.38
Resistance 1 (R1) 22.04 22.03 21.92 21.97 22.33
Pivot Point 21.80 21.80 21.74 21.76 21.80
Support 1 (S1) 21.42 21.56 21.30 21.35 20.99
Support 2 (S2) 21.18 21.41 21.15 20.94
Support 3 (S3) 20.81 21.18 20.89
Support 4 (S4) 20.74